green rings of light


Commercializing curative therapies

Challenges and implications for biopharmaceutical companies

The traditional biopharma business model is being disrupted by biopharma companies ushering potentially curative treatments to market. However, these companies will need to navigate an outdated reimbursement model and challenge traditional commercialization approaches to succeed in the market.

Developing cures is daunting and costly

​Advances in the understanding of disease biology combined with the development of new treatment modalities, including gene and cell therapy, are paving the way for a paradigm shift—from managing a disease to curing it. However, developing and manufacturing cures and treatments for complex diseases can be a daunting and costly process. Biopharma manufacturers ushering potentially curative treatments to market will need to navigate an outdated reimbursement model and a distinct set of challenges related to pricing and market access, biopharma resourcing models, and (for complex treatments) the health care delivery system and manufacturing/supply chain.

So far, success has been elusive.

To date, few cures have come to market—especially highly complex ones—and there is little precedent to help understand how to commercialize them successfully. It is likely, though, that pharmaceutical executives will have to adapt their strategic toolkits to address four key challenges when commercializing curative therapies.

It’s time for a new strategic tool kit

​In the world of curative treatments, cautionary tales continue to outnumber success stories. As commercialization teams prepare to bring cures to market, they will need to consider how one or more of the four challenges may impact their launch choices.

Among the suggested strategic imperatives and actions for biopharma companies to take in commercializing cures are to:

  • Define prioritization and sequencing of patient targets that maximizes the commercial opportunity.
  • Engage the health care ecosystem to drive demand and enable treatment.
  • Build the access foundation that will ensure appropriate coverage and reimbursement for a cure.
  • Create a virtual, lean organization that can rapidly scale capacity for the therapy, especially for high-prevalence/low-incidence indications.​

For more informatinon, read the full report

Read the blog, Curative therapies: Can breakthrough reimbursement models break through financial barriers?

toolbox icon

Get in touch

Rebecca Brian 
Managing director
Deloitte Consulting LLP

Mathias Cousin 
Senior manager
Deloitte Consulting LLP

Marine Serres
Senior manager
Deloitte Consulting LLP

Tom Yang 
Deloitte Consulting LLP

Did you find this useful?